Palisade Bio, Inc.

PALI · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.7%

Institutions101.5%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	$0	–	$13520	$15394	$260000	$260000	$16246	$10417	$18833
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$18.06M	-$14.86M	-$41.85M	-$10.68M	-$8.63M	-$8.26M	-$13.31M	-$20.64M	-$19.16M	-$17.44M
Operating income as a percentage of revenue.	–	–	–	-78961.1%	-56071.8%	-3176.7%	-5118.1%	-127027.2%	-183896.8%	-92581.4%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$16.78M	-$14.44M	-$26.62M	-$16.27M	-$8.35M	-$4.92M	-$15.67M	-$21.07M	-$20.90M	-$22.63M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-0.30	$-10.19	$-2.86	$-1.17	$-3.00	$0.00	$-1.00	$-2.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-0.30	$-10.19	$-3.39	–	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$133.38M	$9.80M	$10.50M	$10.53M	$5.11M	$5.79M	$6.67M	$15.19M	$4.72M	$12.52M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$134.34M	$10.88M	$12.51M	–	$6.58M	$7.68M	$13.88M	$22.60M	$15.05M	$29.84M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	$87000	–	–	–	–	$3.71M	$8.03M	$8.79M
Everything the company owes — debt, unpaid bills, and other obligations.	$4.96M	$3.39M	$5.15M	–	$1.46M	$1.63M	$5.37M	$11.27M	$10.08M	$12.12M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$129.38M	$7.49M	$7.37M	–	$5.13M	$6.05M	$8.52M	$11.33M	$4.97M	$17.72M

Cash Flow Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$10.85M	-$12.19M	-$14.77M	-$9.03M	-$7.26M	-$7.69M	-$13.42M	-$15.62M	-$18.93M	-$11.71M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	$0	$0	–	–	$1714	$11401	$98088	$176272	$207893
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	-$12.19M	-$14.77M	–	–	-$7.69M	-$13.43M	-$15.71M	-$19.11M	-$11.91M

	You	Peer avg
P/E	3.2	2.8
Revenue Growth	–	+102.9%
ROE	-51.4%	-89.1%

Palisade Bio, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison